6533b836fe1ef96bd12a1326
RESEARCH PRODUCT
Phosphatidylserine liposomes reduce inflammatory response, mycobacterial viability and HIV replication in coinfected human macrophages
Noemi PoerioNadia R CaccamoMarco P La MannaTommaso OlimpieriLucia Henrici De AngelisMarco M D’andreaFrancesco DieliMaurizio Frazianosubject
Settore MED/04 - Patologia GeneraleTumor Necrosis Factor-alphaMacrophagesHIVHIV InfectionsMycobacterium tuberculosisPhosphatidylserinesVirus ReplicationSettore BIO/19Host-Directed TherapycoinfectionInfectious DiseasesLiposomesliposomeImmunology and AllergyHumansTuberculosisPhosphatidylserinedescription
AbstractChronic immune activation is the key pathogenetic event of Mycobacterium tuberculosis-human immunodeficiency virus (HIV) coinfection. We assessed the therapeutic value of phosphatidylserine-liposome (PS-L) in an in vitro model of M. tuberculosis-HIV coinfection. PS-L reduced nuclear factor-κB activation and the downstream production of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 in bacille Calmette-Guérin-infected macrophages and of TNF-α and IL-1β in M. tuberculosis-infected and M. tuberculosis-HIV–coinfected macrophages. Importantly, a significant reduction of intracellular M. tuberculosis viability and HIV replication were also observed. These results support the further exploitation of PS-L as host-directed therapy for M. tuberculosis-HIV coinfection.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-08-24 |